Abstract
Sacubitril/valsartan is the first angiotensin II receptor blocker neprilysin inhibitor, which inhibits both angiotensin II receptor and neprilysin. In recent years, a series of clinical studies have shown that sacubitril/valsartan has a good therapeutic effect on heart failure. The present study was conducted to investigate the therapeutic effect and safety of sacubitril/valsartan in patients with cardiac insufficiency during the perioperative period of cardiac surgery. A total of 59 patients were divided into two groups: Heart failure with reduced ejection fraction (HFrEF) group and heart failure with preserved ejection fraction (HFpEF) group. The therapeutic effect on patients with sacubitril/valsartan was assessed by the values of left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVED). The renal safety of patients was assessed by serum creatinine (Cr) and blood urea nitrogen (BUN). Sacubitril/valsartan decreased LVED in HFrEF group and HFpEF group. And it showed a significant increase of LVEF in the HFrEF group. There was no significant change in Cr and BUN. Sacubitril/valsartan showed a good therapeutic effect on cardiac function for the perioperative period of cardiac surgery.